• Australia and New Zealand Gastro-Oesophageal Surgeons Association (ANZGOSA, Current)
• Australia and New Zealand Hepato-Pancreatico-Biliary Association (ANZHPBA, Current)
• International Society for Disease of the Esophagus (ISDE, Current)
• Australian Sarcoma Group (ASG, current)
• Australian Sarcoma Study Group (ASSG, Current)
• Australian Melanoma Trials Group
• American Association for Cancer Research
• Australian Gastrointestinal Trials Group (AGITG, Current)
• International Society of Gastric Cancer (Current)
• Gastroenterological Society of Australia (Current)
• Surgical Research Society of Australasia (Current)
• Clinical Oncological Society of Australia (COSA, Current)
• Gastroenterological Society of Queensland (GESA, Current)
• Royal Australasian College of Surgeons (Current)
• American College of Surgeons (ACS, Current)
• Society of Surgical Oncology (SSO, Current)

1. Secrier M, Li X, de Silva N, Eldridge MD, … Barbour AP et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet. 2016;48:1131-41. First study defining OAC genomic subgroups using whole genome sequencing.
2. Nones K, Waddell N, Wayte N, … Barbour AP. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun. 2014;5:5224. First study to describe chromothripsis in OAC using whole genome sequencing.
3. Krause L, Nones K, Loffler K, … Barbour AP. Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma. Carcinogenesis 2016;37:356-65. First study to demonstrate hypermethylated OAC phenotype associated with poor survival.
4. Bailey P, Chang DK, Nones K, … Barbour A et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016 Mar 3;531(7592):47-52. A landmark publication which characterised the genomic landscape of pancreatic cancer. Characterization of the CNA landscape of OAC and identification of biomarkers of survival.
5. Waddell N…Barbour AP, … Grimmond SM. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015,518:495-501. WGS identified mutational signatures as novel treatment targets in pancreatic cancer.

• 1992 MBBS (Hons), University of Queensland
• 2002 PhD, University of Queensland
• 2003 FRACS, Royal Australasian College of Surgeons

• 2016-current Professor, School of Medicine, University of Queensland
• 2005-current Visiting Surgeon, Greenslopes Private Hospital
• 2005-current Visiting Surgeon, Mater Private Hospital
• 2005-current Visiting Surgeon, Princess Alexandra Hospital
• 2005-current Visiting Surgeon, St Andrew’s War Memorial Hospital
• 2010-2015 Associate Professor, School of Medicine, University of Queensland
• 2005-2009 Senior Lecturer, School of Medicine, University of Queensland

Professor Andrew Barbour is a Surgical Oncologist at the Greenslopes and Mater Private Hospitals, and Princess Alexandra Hospital (PAH) with a research interest in the treatment of cancer. Throughout his career he has maintained a commitment to the academic aspects of surgical practice as well as clinical care. His academic interests have encompassed the areas of 1) clinical research, including randomised controlled clinical trials, 2) laboratory based research, including molecular biology pertinent to upper gastrointestinal disease, 3) translational research integrating the laboratory and clinical domains. He is an author on the Cancer Council Clinical Practice guidelines for the Management of Melanoma, and a Leading Contributor to the Australian Bariatric Registry.

Over the last 5 years, Prof Barbour has been active in the conduct of clinical trials at Phase I, II and III levels. He was the principal investigator of the DOCTOR (NHMRC APP #1011782) and the investigator-initiated, AGITG-sponsored phase II clinical trial of pre-operative chemotherapy for pancreatic cancer (GAP trial). Both of these national trials include biological substudies. Prof Barbour is also a translational researcher and Head of the Surgical Oncology Lab, The University of Queensland. His research group has focused on genomic studies, including whole genome sequencing, methylation, DNA copy number and expression analyses to classify pancreatic cancer, OAC, and melanoma, and to identify biomarkers and drivers of outcome. As a result, he has expertise in whole genome analyses of cancer and the translation of findings to the clinic.

1. 2018-20 Improving outcomes and reducing toxicity for oesophageal adenocarcinoma treatment: genomic analysis of the DOCTOR trial. CIA Waddell, CIB Barbour $998,000
2. 2017 John Mitchell Crouch Fellowship, Royal Australasian College of Surgeons $150,000.
3. 2014-15 Complement C3a receptor, a novel therapeutic target for melanoma. CIA Taylor, CIB Rolfe, CIC Barbour. The Cancer Council Queensland $196,000.
4. 2013-18 PROBE-NET: The Progression of Barrett’s Esophagus to Cancer Network. CIA Whiteman, CIF Barbour. NHMRC CRE $2,465,841
5. 2012-14 Whole genome analyses of oesophageal adenocarcinoma. NH&MRC APP1021403 CIA Barbour, Waddell, Krause, Nancarrow, Hussey, Watson, Lord. $957,987
6. 2012-14 Personalising care in operable pancreas cancer. A study of imaging and molecular biomarkers to guide treatment of patients receiving preoperative chemotherapy followed by surgery. NH&MRC APP1026563. CIA Barbour. $391,987
7. 2011-15 DOCetaxel with or without radiation Therapy for resectable Oesophageal adenocarcinoma based on early PET Response to induction chemotherapy (DOCTOR). NH&MRC APP1011782. Chief Investigators: CIA Barbour $791,991.42

Career publications as of March 2018: A total of 80 including 73 journal articles and 7 reviews. Publications include Nature, Nature Communications, Gastroenterology, Carcinogenesis, Genes, Chromosomes and Cancer, Lancet Oncology, Annals of Surgery and British Journal of Surgery.

• 2019 Invited Speaker, International Gastric Cancer Congress, Prague.
• 2018 Invited Speaker American Society of Clinical Oncology, GI symposium, San Francisco, USA.
• 2017 Invited Speaker Malaysian College of Surgeons Annual Scientific Congress, Kuching, Malaysia.
• 2017 Invited Speaker, Royal Australasian College of Surgeons, Annual Scientific Meeting, Adelaide.
• 2017 Invited Speaker, Singapore Gastric Cancer Consortium, Annual Scientific Meeting, Singapore.
• 2016 Invited speaker: Asia Pacific Gastric Cancer Conference, Seoul. “GEJ Cancer Classification and Staging” and session chair.
• 2016 Invited Speaker: Lorne Cancer Conference, Lorne. “Genomic Catastrophes Driving Tumorigenesis in Oesophageal Adenocarcinoma”
• 2013-14: James IV Travelling Fellow. Visiting Professor to Queen Mary Hospital, Hong Kong; Seoul National University Hospital, Seoul; Cancer Institute Hospital, Tokyo; Karolinska Institute, Stockholm; Erasmus Medical Centre, Rotterdam; and Nationale Instituto Tumori, Milan.
• 2015 Invited Speaker: Asia Pacific Gastric Cancer Conference, Brisbane. 4 presentations.
• 2014 Invited speaker: Australian Health and Medical Research Conference, Melbourne. “Genomic Catastrophes in Oesophageal Adenocarcinoma.”
• 2013 Invited speaker: OESO 12th World Conference, Paris. “How Useful is Tumour Analysis?”
• 2013 Invited speaker: Gastroenterological Society of Australia (GESA), Annual Scientific Meeting, Melbourne. “Molecular Fingerprints: Where Are We Now?”
• 2012 Invited speaker: Australian Health and Medical Research Conference, Adelaide. “Genomic Aberrations in Oesophageal Adenocarcinoma.”
• 2010-13 Invited speaker: Australia & New Zealand Gastric & Oesophageal Surgeons Association

Peer review journals: Nature Communications, Gastroenterology, PLoS One, British Journal of Cancer, British Journal of Surgery, Annals of Surgical Oncology, BMC Cancer, ANZ Journal of Surgery.

Peer review for granting agencies: NH&MRC (2010); Medical Research Council, UK (2009 & 2015); Cancer Australia panel (2012); NH&MRC Grant Review Panel (2013 & 2015); NH&MRC Assigner Academy (2014).

Scientific committee membership: 2009-current Member, Australasian Gastrointestinal Trials Group (AGITG) Scientific Advisory Committee; 2009-current Management Committee of the Queensland Cooperative Oncology Group; 2009-current AGITG Annual Scientific Meeting; AGITG Board Memeber

Since 2008 CIA has supervised several post-graduate students including 4 PhD and 1 masters students. In addition he supervises junior medical staff and 3 full time post-doctoral researchers.